A Phase 3 Study to Evaluate the Efficacy of XW003 Compared With Dulaglutide in Participants With T2DM
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 623 participants.
Also called NCT05680129
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 623 participants
- Sponsor
- Hangzhou Sciwind Biosciences Co., Ltd.
- Registry
-
NCT05680129
-
- Other papers using this trial's data
- Efficacy and safety of cAMP-biased GLP-1 receptor agonist ecnoglutide versus dulaglutide in patients with type 2 diabetes and elevated glucose concentrations on metformin monotherapy (EECOH-2): a 52-week, multicentre, open-label, non-inferiority, randomised, phase 3 trial
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- China
- Registry status
- Completed
Technical summary
Registry record NCT05680129. Randomized; no masking; primary purpose treatment. Start 2023-01-10 (actual); primary completion 2024-07-03 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- A Phase 3 Study to Evaluate the Efficacy of XW003 Compared With Dulaglutide in Participants With T2DM
- Condition
- T2DM
- Condition
- Type 2 Diabetes Mellitus
- Intervention (Drug)
- Ecnoglutide high dosage
- Intervention (Drug)
- Ecnoglutide low dosage
- Intervention (Drug)
- Dulaglutide
- Intervention (Drug)
- Metformin
- Lead sponsor
- Hangzhou Sciwind Biosciences Co., Ltd.
Record details
- Record id
cardio:ct-nct05680129- Content hash
6d58cab0c6f5f52c6580f6063f2912b8ec3486a5b0a34318ea493e911788a90a